Mucohexin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucohexin

Property Description
Active ingredient Bromhexine hydrochloride
Form Tablet, oral suspension (syrup/liquid), solution
Pharmacological class Mucolytic and Secretolytic Agent
General purpose Aid in mucus clearance
Origin Synthetic derivative (of vasicine)

Defining Mucohexin: Classification and Active Ingredient

Mucohexin is a dedicated pharmaceutical preparation that functions as an oral mucolytic agent used to manage conditions characterized by excess phlegm in the respiratory system. Its therapeutic action is delivered solely by the active substance, Bromhexine, typically formulated as the hydrochloride salt, and is classified under the Anatomical Therapeutic Chemical (ATC) system as a mucolytic. The drug belongs to the high-level pharmacological class of secretolytics and expectorants, clearly distinguishing it from medicines that suppress a cough. It acts on the properties of mucus rather than the cough reflex itself, positioning it for effective secretion management.


Composition, Origin, and Available Drug Forms

The efficacy of Mucohexin is centered on Bromhexine, a highly potent synthetic derivative developed from the natural plant alkaloid vasicine. This chemical lineage ensures the product is standardized and highly reliable. Mucohexin is fundamentally a single-ingredient product (monotherapy), ensuring its effects are attributed entirely to the mucolytic properties of its active component. For user convenience and adaptability, the drug is prepared for oral administration in several readily available dosage forms, including the common tablet, the easily swallowed oral suspension (syrup/liquid), and various solutions.


General Therapeutic Purpose

The general therapeutic purpose of Mucohexin is to support the body's natural processes by targeting and transforming thick, sticky airway secretions. It achieves this by reducing the viscosity of mucus, a fundamental action that makes the phlegm thinner and more fluid. This liquefaction and thinning action facilitates improved mucus clearance from the bronchi and lungs, a process supported by its secretomotoric effects. Ultimately, this helps patients experience easier expectoration and more efficient respiration by preventing the obstructive build-up of tenacious mucus.

What side effects are possible with Mucohexin?

Possible Side Effects and Safety Information

The official safety profile for Mucohexin (Bromhexine hydrochloride) is established through regulatory classifications based on the frequency and type of documented adverse reactions. These effects are grouped according to the body system affected, known as System-Organ Classes.

Adverse Reaction Classifications

The most frequently reported adverse effects in regulatory documents are classified as Rare (occurring in 1 to 10 users in 10,000) and primarily involve Gastrointestinal Disorders such as nausea, vomiting, and diarrhoea. Other rare effects may include skin reactions like rash or urticaria (hives).

Reactions classified as Very Rare include headache, dizziness, and a transient rise in liver enzyme levels (serum aminotransferase).

Serious Safety Considerations

Official labeling explicitly includes warnings for rare but serious adverse reactions, which have a frequency of Not Known (cannot be estimated from available data). These include severe allergic responses such as Anaphylactic Shock and Angioedema, as well as Severe Cutaneous Adverse Reactions (SCARs). SCARs encompass life-threatening skin conditions like Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN).

Population-Specific Safety Notes

Safety documents specify the need for caution in patients with a history of peptic or gastric ulceration and those with severe hepatic or renal impairment. Use is generally not recommended during the first trimester of pregnancy and during breastfeeding. Additionally, caution is noted in asthmatic patients due to the documented risk of bronchospasm.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Mucohexin (Bromhexine) focuses primarily on mandated emergency action due to the nature of overdose reporting.

Overdose Scope (Official Regulatory Findings) Description
Documented Presentations No specific overdose symptoms have been reported in man following acute overexposure. Observed symptoms are generally consistent with known adverse effects, which may include nausea, vomiting, diarrhoea, epigastric pain, headache, and dizziness. A pharmacological effect noted is a potential increase in bronchial secretions.
Severity Classification Regulatory assessments indicate no significant toxicity or death has been explicitly linked to Bromhexine overexposure.

The regulatory consensus mandates that immediate action must be taken in any suspected overdose scenario. Immediate medical attention must be sought, and the Poisons Information Centre or a doctor must be contacted immediately, even if no signs or symptoms are presently apparent. This urgent requirement is necessary because no specific antidote is known for the active substance. Management of overexposure is consistently defined in regulatory texts as symptomatic and supportive treatment, administered under professional supervision. Regulatory documents do not detail unique altered overdose manifestations for specific populations.

Therapeutic Uses of Mucohexin

The primary therapeutic role of Mucohexin (Bromhexine) is to provide targeted symptomatic support for conditions characterized by impaired mucus clearance and congestion in the respiratory tract. Its use is aligned with specific symptom patterns and clinical contexts, focusing exclusively on easing the burden of difficult secretions.

Mucohexin is commonly used across conditions presenting with acute episodes and recurrent manifestations. It may be part of symptomatic management in cases such as chronic bronchitis, COPD, or acute conditions like the common cold and influenza.

Mucohexin is applied across domains where additional symptomatic support is needed when patients experience symptoms related to the presence of thick phlegm or an ineffective productive cough. By providing assistance for the difficulty of the phlegm, the medication may help patients cope more steadily with symptoms that interfere with daily comfort, providing support that helps ease the overall symptom burden.

“Mucohexin is commonly used to address groups of symptoms that cluster into patterns requiring supportive management, focusing on respiratory discomfort.”

This application may assist with supporting functional stability by managing symptoms that become more disruptive during flare-ups and contributes to easing the overall symptom load. It is relevant for easing symptoms that may create noticeable physiological strain, offering symptomatic relief that may help patients cope more steadily with difficult episodes.


Quick Fact: Relief for Thick, Stubborn Phlegm Mucohexin is commonly used when short-term symptomatic assistance is needed to support easier expectoration (coughing up of phlegm), which may support patients during difficult episodes by helping ease distress.

Regulatory References

  1. Therapeutic Goods Administration (TGA) Monograph

Eligibility and Restrictions for Use

Who Can and Cannot Use Mucohexin?

Population eligibility for Mucohexin (Bromhexine) is strictly defined by regulatory authorities based on contraindications, age limits, and physiological status.

Contraindications and Non-Eligibility

Mucohexin is contraindicated in patients with a known hypersensitivity to bromhexine hydrochloride or any excipients present in the formulation. Specific liquid formulations are also contraindicated in patients with rare hereditary problems of fructose intolerance. Usage is also contraindicated for children under 6 years of age in many regulatory regions.

Restricted and Conditional Use

Population Group Regulatory Status
Children 6 to 11 years Use is often conditional and requires the advice of a healthcare professional.
Severe Hepatic/Renal Impairment Must be used with caution; accumulation of the drug or its metabolites may occur.
History of Gastric Ulceration Use with caution due to the potential effect on the gastric mucosal barrier.

Pregnancy and Lactation

Mucohexin is not recommended for use during pregnancy, especially the first trimester, and is not recommended for use by breastfeeding mothers, as the active substance is known to be excreted in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Mucohexin (Bromhexine) defines interactions based on pharmacodynamic conflict, therapeutic synergy, and pharmacokinetic considerations. It is officially noted that no clinically relevant unfavorable interactions with other general medicines have been reported during extensive post-marketing surveillance.

Prohibited Combinations Co-administration with antitussives (cough suppressants) and medicines that reduce bronchial secretions is prohibited. This restriction is classified as a mandatory exclusion based on a pharmacodynamic conflict: the secretolytic action of Mucohexin increases bronchial fluid, and suppressing the necessary cough or secretion-clearing mechanism can result in the retention and accumulation of stagnant phlegm in the respiratory tract.

Pharmacodynamic Effects A documented interaction exists with specific antibiotics, including Amoxycillin, Erythromycin, and Oxytetracycline. Regulatory data confirms that co-administration leads to a desirable increase in the concentration of these antibiotics within the sputum and bronchopulmonary secretions.

Exposure and Clearance A pharmacokinetic interaction is documented with food intake, which results in an increase in the plasma concentrations of Bromhexine. Official prescribing information also notes a specific constraint for patients with severe hepatic impairment or severe renal impairment, as the clearance of the medicine and its metabolites may be reduced, potentially altering systemic exposure in these specific populations.

Mechanism of Action

Mucohexin (Bromhexine) is widely distributed, exhibiting selective accumulation within pulmonary tissue. Its primary biological target is the Transmembrane Protease Serine 2 (TMPRSS2), which it interacts with as an inhibitor. This molecular interaction prevents the enzymatic cleavage and subsequent activation of specific proteins required for cellular processes.

The mechanism also involves hydrolytic action on the acidic mucopolysaccharide fibers present in respiratory secretions. This molecular pathway of depolymerization leads to the reduction of sputum viscosity. Mucohexin is also observed to activate the serous glands in the bronchial mucosa. This activation is followed by a downstream cascade of increased lysosome synthesis and activity, which enhances the secretion of lysosomal enzymes (specifically lysozyme). These enzymes contribute further to the hydrolysis of mucin glycoproteins.

At a system-level, the consequence of these intracellular pathways is a modulation of the rheological properties of mucus, resulting in a quantifiable decrease in the overall tenacity and stickiness of the bronchial secretions.

Dosage and Administration Information

How to Use Mucohexin (Ambroxol Hydrochloride)

Administration and Dosage

Mucohexin is available for oral use (tablets, syrup, lozenges, effervescent tablets) and in specialized forms for intravenous, inhalative, or rectal administration.

Patient Group Recommended Dosing Regimen Frequency
Adults (Oral) Total daily dose between 30 mg and 120 mg. 2 to 3 times daily
Children 2-5 Years (Syrup) 7.5 mg (e.g., 2.5 ml of 15 mg/5 ml syrup). 3 times daily
Children >5 Years (Syrup/Tablet) 15 mg (e.g., 5 ml of syrup) or 30 mg tablet. 2 to 3 times daily

Preparation and Procedural Instructions

  1. Oral Administration: Tablets and lozenges are taken whole. Effervescent tablets must be fully dissolved in a liquid (such as water) before they are consumed. The syrup or oral solution must be measured using the specific measuring device provided.
  2. Missed Dose: If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time. Do not attempt to take a double dose to make up for the missed one.
  3. Timing: The medicine can generally be taken with or without food.

Special Use Conditions

  • Infants and Newborns: Intravenous, rectal, or other specialized formulations are used by healthcare professionals in clinical settings for specific conditions in newborns and infants.
  • Lozenge Use: The lozenge formulation is typically authorized for adults and children over 12 years of age for oromucosal administration.

Recent Clinical Evidence

Mucohexin: Recent Clinical Evidence

This overview summarizes the official research conducted on Mucohexin (Bromhexine), describing the types of studies that exist and what they explored, without offering any medical advice or treatment recommendations. The research describes the drug's role as a mucolytic agent in conditions associated with thick mucus in the airways.


Research on Established Mucolytic Use

Studies exploring the use in conditions characterized by fluctuating or episodic manifestations, such as chronic bronchitis and acute respiratory conditions, utilized Randomized Controlled Trials (RCTs). Researchers primarily examined outcomes related to physical discomfort and symptom intensity, focusing on the characteristics of the patient’s sputum. Data show patterns related to how the stickiness (viscosity) of sputum was observed to change, and trials described patient-reported outcomes describing perceived discomfort related to the ease of expectoration.

However, the data show patterns related to objective measures of lung function—such as overall airflow or ventilatory capacity—were mixed or inconsistent across different studies. For acute conditions, the research was studied for its application in research scenarios exploring short-term symptom changes, but high-quality comparative evidence is lacking for the most common infections.


Study Duration and Specific Groups

For the medication’s established uses, follow-up durations in the primary clinical trials were limited, often lasting only one to three weeks. The long-term effects are not fully established by the existing published regulatory research, and data are still emerging regarding continuous use. Mucohexin was evaluated in studies that included adults and older adults. However, the scientific record indicates that research focusing solely on the primary mucolytic effect in young children is limited, and data for certain groups remain insufficient.


Key Research Gaps and Unanswered Questions

The evidence highlights what is known—and what is still uncertain. The findings were mixed regarding its impact on standard measures of functional imbalance in the lungs. Furthermore, Mucohexin was studied for novel applications based on its potential to affect certain cellular pathways in the context of severe viral respiratory illnesses. Research in this area involves small-scale pilot studies. This is currently Low-level evidence, and the certainty remains low for any of these novel applications, which are based on a different research scenario than its established use. The research does not determine whether an individual will respond similarly to the observed group patterns.

Key Studies & References

  1. Therapeutic Goods Administration (TGA) Monograph: Bromhexine Hydrochloride
  2. WHO Collaborating Centre for Drug Statistics Methodology: ATC Index R05CB02 Bromhexine
  3. ClinicalTrials.gov: Study of Bromhexine in Patients with COVID-19 (used to illustrate novel research scenarios)

Frequently Asked Questions (FAQ)

Common questions about Mucohexin (FAQ)

Q: Is Mucohexin available without a prescription?

A: Mucohexin's legal status varies by location. In many regions, the medicine is regulated as an over-the-counter (OTC) product, meaning it can be purchased directly from a pharmacy without a doctor’s prescription. This classification is determined by the local governing health authority.

Q: What is the main difference between Mucohexin and other similar cough medicines?

A: Official information defines Mucohexin as a mucolytic and secretolytic agent, meaning its primary action is thinning and loosening mucus. This therapeutic role differentiates it from antitussives, which are medicines that work by suppressing the cough reflex itself.

Q: How long does it usually take for Mucohexin to start working?

A: A specific time-to-relief is typically not specified on the product label. However, the regulatory documentation describes the active substance as being rapidly absorbed into the bloodstream, initiating the pharmacological process.

Q: How long can I continue taking Mucohexin before needing to stop?

A: Health authority guidance often states that if symptoms persist or worsen after about one week of use, consultation with a healthcare professional is advised. Existing studies have often focused on short-term outcomes, which is why continuous use may require clinical review.

Q: Is it okay to take Mucohexin with my daily multivitamin?

A: Official labeling has not reported any clinically relevant unfavorable interactions with general over-the-counter medicines or vitamins. However, co-administration is prohibited with cough suppressants (antitussives) and other medicines that reduce bronchial secretions.

Q: What should I do if my symptoms don't improve while taking Mucohexin?

A: If symptoms persist or worsen after approximately one week of use, regulatory guidance advises seeking consultation with a healthcare professional. This allows for a proper review of the condition and the next steps for care.

Q: Is there any information about Mucohexin use during pregnancy?

A: Official product information states that Mucohexin is not recommended for use during pregnancy, especially within the first trimester. This is due to a lack of complete safety data and the fact that the active substance is known to cross the placental barrier.

Q: What is the evidence regarding Mucohexin use in breastfeeding mothers?

A: Mucohexin is not recommended for use by breastfeeding mothers. Regulatory documents confirm that the active substance in the medicine is known to be excreted into breast milk.

Q: Why is there a specific instruction about the maximum duration of use?

A: The restriction on long-term use is based on the research available. Regulatory studies typically had limited follow-up durations, often only a few weeks. This limitation in clinical trial duration is why continuous, long-term use is often conducted under appropriate supervision.

Q: Can I take Mucohexin if I have kidney problems?

A: Regulatory documents state that use is specified to be with caution in patients with severe hepatic (liver) or severe renal (kidney) impairment. This is because reduced liver or kidney function can affect how the body clears the medicine and its metabolites.

Q: Does Mucohexin cause drowsiness or make you tired?

A: Official safety documents do not commonly list general tiredness or drowsiness as an adverse effect. However, dizziness (vertigo) has been reported as a very rare or rare adverse reaction in some users.

Q: Can I drive or operate machinery after taking Mucohexin?

A: Official information advises caution regarding driving or operating heavy machines. If you experience side effects such as dizziness or headache, official information indicates that engaging in these activities should be avoided.

Q: What are the non-drug ingredients in Mucohexin tablets?

A: Official documentation provides a full list of excipients (non-active ingredients) in the formulation. These ingredients typically include fillers, binding agents, and flavorings, such as lactose in some tablet forms or maltitol liquid in certain syrup forms.

Q: Is there a generic version of Mucohexin available?

A: Mucohexin is the brand name for the active ingredient, Bromhexine hydrochloride. In many health systems, generic products that contain the same active ingredient are available under the chemical name Bromhexine.

Q: Has Mucohexin been studied in people with chronic lung conditions?

A: The available research has focused on the use of Mucohexin in conditions characterized by thick mucus, including scenarios like chronic bronchitis and acute respiratory issues associated with fluctuating or episodic symptoms.

Q: Does Mucohexin affect blood pressure or heart rate?

A: According to the official safety profile, changes in blood pressure or heart rate are generally not listed as common or rare adverse reactions associated with the use of this medicine.

Q: Why are there different strengths or formulations of Mucohexin?

A: The availability of different strengths (dosing) and formulations, such as tablets, syrups, and lozenges, is intended to accommodate varying patient needs. This includes tailoring the medicine for different age groups and suitable routes of administration.

Q: Is it normal to feel a slight headache after taking Mucohexin?

A: Headache is listed in official regulatory documents as a Very Rare adverse reaction. This classification means that the effect is expected to occur in fewer than 1 in 1,000 users of the medicine.

Q: Does Mucohexin contain gluten or lactose?

A: Official product information, specifically the list of excipients, details the ingredients present. Some tablet formulations are noted to contain lactose. It is necessary to refer to the specific formulation’s official label for confirmed information regarding the presence of gluten or other specific ingredients.

Q: How is Mucohexin eliminated or broken down by the body?

A: Mucohexin is primarily metabolized (broken down) in the liver and is then eliminated from the body, mostly as inactive metabolites, through the urine. This metabolism and elimination process is why caution is advised for patients with severe liver or kidney impairment.

Q: What is the significance of the letters/numbers sometimes attached to the drug name?

A: The letters and numbers, such as R05CB02, are part of the Anatomical Therapeutic Chemical (ATC) Classification System. This is a standardized code used by global health authorities to categorize the medicine based on its primary therapeutic action in the body.

Q: Can Mucohexin be taken on an empty stomach?

A: The medicine can generally be taken with or without food. However, official prescribing information notes that taking the medicine with food results in an increase in the plasma concentrations (amount in the blood) of the active substance.

Q: Are there any documented cases of overdose with Mucohexin?

A: Official regulatory labeling indicates that specific overdose symptoms have generally not been reported in humans. Any symptoms observed after accidental overdose are typically described as consistent with the known side effects at recommended doses.

Q: What is the difference in how the liquid and tablet forms of Mucohexin work?

A: The active substance, Bromhexine, works the same way to thin mucus regardless of whether it is in a tablet or liquid form. The difference in formulation primarily relates to administration, though the liquid form may sometimes have minor differences in its rate of absorption compared to the solid tablet form.

Q: What are the typical signs that Mucohexin is having its intended effect?

A: The drug's intended action is the reduction of mucus viscosity and facilitation of mucus clearance from the airways. For the patient, this process is expected to result in easier expectoration, meaning the phlegm is easier to cough up.

How should Mucohexin be stored and disposed of?

How to Store and Dispose of Mucohexin

Storage and disposal of Mucohexin (bromhexine) must strictly follow the conditions specified in the official regulatory labeling to maintain the product's stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at temperatures not exceeding 30^circC (86°F), or as specifically directed on the label.
Protection The medicine must be protected from excessive heat, moisture, and light.
Container Keep the product in its original container and ensure the cap or closure is kept tightly closed.
Child Safety It is mandatory to keep Mucohexin out of the sight and reach of children.

Disposal Instructions

Unused or expired Mucohexin must be disposed of in accordance with local requirements for pharmaceutical waste. Regulators advise utilizing official drug take-back programs or authorized collection sites when available. The product should not be flushed down a toilet or poured into a drain unless explicitly stated in the product's official instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mucohexin found in:

A-Z Index: